WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-sca...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) announced the U.S. Food and Drug Administrati...
PHC is a subsidiary of PHC Group*1, a global healthcare company that develops, manufactures, sells, and services solutions across the business domains of d...
Ideal for the transportation of life-saving pharmaceutical, biotech and life-science products, Tower’s robust, reliable, reusable solutions are a wel...
The Pipette Manager serves as a wireless control panel for Eppendorf's connected electronic pipettes, adding new features and revolutionizing the speed and...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...
Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation fur...
TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug d...
Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Survey of 7,000+ people in Asia shows expectation of early retirement, early deterioration in health Concerns about cost of well-being nu...
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
© 2026 Biopharma Boardroom. All Rights Reserved.
